SCHEMBL727389

SCHEMBL727389

O=C(O)c1cc2c(Cl)cc(Cl)cc2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 3/20 1.00
RHEB Q15382 8/20 0.76
EIF4A3 P38919 1/20 0.64
MEN1 O00255 2/20 0.63
CYP2C9 P11712 2/20 0.63
HPGD P15428 2/20 0.63
BLM P54132 2/20 0.63
KMT2A Q03164 2/20 0.63
GRIN2D O15399 2/20 0.63
GRIN3B O60391 2/20 0.63
GRIN2A Q12879 2/20 0.63
GRIN2B Q13224 2/20 0.63
GRIN2C Q14957 2/20 0.63
GRIN3A Q8TCU5 2/20 0.63
CYP1A2 P05177 1/20 0.63
CYP2D6 P10635 1/20 0.63
ALOX15 P16050 1/20 0.63
TSHR P16473 1/20 0.63
CYP2C19 P33261 1/20 0.63
TDP1 Q9NUW8 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29531428 1.00 GRIN1 (1.00) GRIN1RHEBEIF4A3MEN1CYP2C9
SCHEMBL20535612 0.86 RHEB (1.00) GRIN1RHEBEIF4A3MEN1CYP2C9
SCHEMBL3033007 0.85 GRIN1 (0.74) GRIN1RHEBEIF4A3MEN1CYP2C9
SCHEMBL22529402 0.84 GRIN1 (0.72) GRIN1RHEBEIF4A3MEN1CYP2C9
SCHEMBL20505089 0.84 GRIN1 (0.72) GRIN1RHEBEIF4A3MEN1CYP2C9
SCHEMBL13956187 0.84 GRIN1 (0.72) GRIN1RHEBEIF4A3MEN1CYP2C9
SCHEMBL1144772 0.84 GRIN1 (0.72) GRIN1RHEBEIF4A3MEN1CYP2C9
SCHEMBL30310414 0.84 GRIN1 (0.72) GRIN1RHEBEIF4A3MEN1CYP2C9
SCHEMBL15515831 0.82 GRIN1 (0.70) GRIN1RHEBEIF4A3MEN1CYP2C9
SCHEMBL29974385 0.82 GRIN1 (0.70) GRIN1RHEBEIF4A3MEN1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718633-B2 Indole compounds, process for the preparation and use thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2023-08-08 US claimed
US-20210238204-A1 INDOLE COMPOUNDS, PROCESS FOR THE PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2021-08-05 US claimed
EP-2167077-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR Bayer Schering Pharma Aktiengesellschaft (DE) 2010-03-31 EP claimed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 US claimed
WO-2008152099-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 WO claimed
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US claimed
WO-2007121154-A2 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 WO claimed
US-6818655-B2 2-AMINOQUINOLINES; CARDIOVASCULAR, GASTROINTESTINAL, PYSCHOLOGICAL, RESPIRATORY AND NERVOUS SYSTEM DISORDERS SMITHKLINE BEECHAM CORPORATION 2004-11-16 US claimed
EP-1359915-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM (US) 2004-07-21 EP claimed
US-20040063757-A1 Urotensin-ll receptor antagonists SMITHKLINEE BEECHAM CORPORATION 2004-04-01 US claimed
EP-1359915-A1 UROTENSIN-II RECEPTOR ANTAGONISTS Smithkline Beecham (US) 2003-11-12 EP claimed
WO-2002058702-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (GB) 2002-08-01 WO claimed
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS PARDES BIOSCIENCES INC (US) 2026-04-30 US disclosed
EP-4660193-A1 INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2025-12-10 EP disclosed
US-20250302825-A1 COMBINATION TREATMENTS FOR DEPRESSION UTILIZING AN NMDAR ANTAGONIST GLYTECH LLC (US) 2025-10-02 US disclosed
US-20250243187-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-07-31 US disclosed
WO-1994027964-A1 3-(INDOL-3-YL) PROPENOIC ACID DERIVATIVES AND AS NMDA ANTAGONISTS MERRELL DOW PHARMACEUTICALS INC. (US) 1994-12-08 WO disclosed
US-5360814-A NMDA antagonists MERRELL DOW PHARMACEUTICALS INC. (US) 1994-11-01 US disclosed
WO-1994007500-A1 2,5-DIHYDRO-2,5-DIOXO-1H-AZEPINES AND 2,5-DIHYDRO-2-OXO-1H-AZEPINES AND THE USE THEREOF AS EXCITATORY AMINO ACID AND GLYCINE RECEPTOR ANTAGONISTS WEBER ECKARD (US) 1994-04-14 WO disclosed
EP-0501378-A1 NMDA Antagonists MERRELL DOW PHARMACEUTICALS INC. (US) 1992-09-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K2 GRIN1 1234/4885RHEB 1062/4885EIF4A3 870/4885
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS CTRC, CTRL, CTSL GRIN1 2987/4885RHEB 1539/4885EIF4A3 566/4885
US-20250243187-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 GRIN1 2839/4885RHEB 1079/4885EIF4A3 195/4885
US-20040063757-A1 Urotensin-ll receptor antagonists UTS2R, PLAUR, SCTR GRIN1 1735/4885RHEB 3408/4885EIF4A3 4643/4885
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 GRIN1 1648/4885RHEB 3847/4885EIF4A3 3270/4885
US-11718633-B2 Indole compounds, process for the preparation and use thereof IDO1, IDO2, INMT GRIN1 4291/4885RHEB 1162/4885EIF4A3 3850/4885
US-20210238204-A1 INDOLE COMPOUNDS, PROCESS FOR THE PREPARATION AND USE THEREOF IDO1, IDO2, INMT GRIN1 4291/4885RHEB 1162/4885EIF4A3 3850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.